论文部分内容阅读
血管加压素—神经垂体激素载体蛋白(hNPI)是活性九肽加压素(AVP)的前体分子,神经分泌颗粒通过出胞作用将AVP和hNPI同时释入血液和脑脊液。在各种生理和病理情况下,hNPI的浓度可反映出AVP释放的变化,而血浆和脑脊液hN-PI水平较AVP更为稳定。 近20年来,越来越多的证据表明,AVP对动物和人类的情绪、记忆和选择性注意有中枢激活作用。有报道显示,抑郁和躁狂症时,AVP的释放可能有改变。本文作者首次报告了一例未用过药并从未接受过锂盐治疗的双相抑郁症患者,血浆AVP、相关肽水平的变化情况。
Vasopressin, a neurophysin receptor protein (hNPI), is a precursor molecule of active nonapeptide vasopressin (AVP), a neurotransmitter that simultaneously releases AVP and hNPI into the blood and cerebrospinal fluid via exocytosis. Under various physiological and pathological conditions, hNPI concentrations reflect changes in AVP release, whereas hN-PI levels in plasma and cerebrospinal fluid are more stable than AVP. Over the past two decades, there is growing evidence that AVP has a central activation effect on mood, memory and selectivity in animals and humans. It has been reported that the release of AVP may be altered in depression and mania. The authors first reported the change of plasma AVP, related peptide levels in a bipolar depression-naive patient who had never received lithium treatment.